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Abstract
OBJECTIVE: To explore the use of Xinfeng capsule
(XFC) in the treatment of active rheumatoid arthri-
tis (RA) and its effect on immunoglobulin titer, B
cell-activating factor (BAFF) and its receptor
(BAFF-R).
METHODS: A multi-center randomized, double-
blind, parallel-controlled study was conducted. 45
RA patients were assigned to two groups: one was
treated with XFC plus the placebo for leflunomide
(LEF) and the second group was treated with LEF
plus XFC placebo, for 12 weeks. The clinical and lab-
oratory parameters were collected at baseline and
at 12 weeks.
RESULTS: After 12 weeks of treatment, patients in
the two groups all showed an therapeutic effect
when ACR20, ACR50 and ACR70 were compared,
but the differences between two groups were not
significant (P < 0.05). The serum levels of IgG1,
BAFF and BAFF-R in the XFC group were lower than
those in the LEF group (P < 0.05). The level IgG sub-
types correlated with clinical parameters; IgG2 lev-
els positively correlated with C-reactive protein
(CRP) (P < 0.01); IgG3 levels positively correlated
with white blood cell count and CRP (P < 0.01);
IgG4 levels positively correlated with Complement
4 ( C4 ) (P < 0.01); the level of BAFF negatively corre-
lated with Lymphocyte ( LYMPH# ) (P < 0.01); how-
ever, BAFF-Rpositively correlatedwithPlatelet ( PLT )
and a1-acid glycoprotein (AGP) (P < 0.01).
CONCLUSION: XFC can regulate the level of BAFF/
BAFF-R in active rheumatoid arthritis and improve
the levels of immunoglobulins in RA patients.
© 2015 JTCM. All rights reserved.
Key words: Arthritis, rheumatoid; Xinfeng capsule;
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INTRODUCTION
Rheumatoid arthritis (RA) is a severe autoimmune dis-
ease. Leflunomide (LEF) is commonly used for the im-
munosuppressive treatment of RA.1 It can inhibit di-
hydroorotate dehydrogenase activity and influences the
pyrimidine nucleotide synthesis pathway. It also inhib-
its the activity of tyrosine kinases preventing signal
transduction and T cell activation. Furthermore, leflun-
omide's metabolites are thought to affect the produc-
tion of metalloproteinases by synovial fibroblasts and
may inhibit the synthesis of nitric oxide (NO).2
Xinfeng capsule (XFC) is a Chinese patent medicine
that has been widely used in the clinical treatment of
RA. It consists of Huangqi (Radix Astragali Mongolici),
626
JTCM |www. journaltcm. com December 15, 2015 |Volume 35 | Issue 6 |
WangYL et al. / Clinical Study
Yiyiren (Semen Coicis), Wugong (Scolopendra) and
Leigongteng (Radix et Rhizoma Tripterygii), which are
components based on the theory of monarch, which
means basic principles of compatibility of prescrip-
tions. XFC has the effect of supplementing Qi,
strengthening the spleen and promoting blood circula-
tion.3 Huangqi (Radix Astragali Mongolici) and Yiyiren
(Semen Coicis) are sovereign drugs, which play a major
role, and can enhance immunity, are anti-inflammato-
ry and protective of gastric mucosa.4,5 Wugong (Scolo-
pendra) and Leigongteng (Radix et Rhizoma Tripterygii)
are minister drugs, which play a secondary role, and
are anti-inflammatory and can regulate immunity and
microcirculation.4,5 Existing studies show that XFC can
effectively regulate the serum levels of cytokines in RA
patients and Adjuvant arthritis rat ( AA rats) ; these cy-
tokines include interleukin (IL)-1b tumor necrosis fac-
tor (TNF)-a, IL-4 and IL-10.6,7 The high-performance
thin-layer chromatography (HPTLC) fingerprint chro-
matographic for the evaluation of XFC is shown in pre-
liminary studies.8 Fingerprint is based on the research
of chemical components of Chinese medicine, which is
mainly used in the evaluation of authenticity, quality
and stability.
In several clinical trials, the progression of RA was
closely related to the dysfunction of B lymphocytes.9-11
B cell-activating factor (BAFF) is a member of the
TNF super family, which plays an important role in
the regulation of both the innate and adaptive immune
responses.12 Studies have shown that serum BAFF lev-
els in patients with active RA were significantly higher
than those in normal subjects. Therefore, we analyzed
the levels of BAFF/BAFF-R in 45 patients with RA,
along with the levels of immunoglobulin (Ig) G (sub-
types 1-4), IgA, and IgM, following treatment with
XFC.
MATERIALS ANDMETHODS
Study population
Eligible patients were between 18 and 65 years of age
and had been diagnosed with active RA based on the
American Rheumatism Association (ACR) 1987 re-
vised criteria.13 They were classified into functional
classⅠ orⅢ according to the Modified Disease Activi-
ty Score (3 variables; DAS28-3)14 promulgated by the
European Union of anti-rheumatism. The disease activ-
ity of RA patients and classification was judged by
DAS28-3. Patients were excluded if they were taking
corticosteroids (≤ 15 mg prednisone or equivalent) ≥ 4
weeks before entering the trial, if they had high disease
activity (DAS28-3 scores > 5.1) or they were diagnosed
as suffering any other chronic inflammatory disease or
connective tissue disease, such as Sjögren syndrome, or
systemic lupus erythematosus.. Additionally, patients
were excluded from the study if they suffered severe dis-
ease of the cardiovascular system, brain, lung, liver, kid-
ney, gastrointestinal system or hematopoietic system,
were pregnant or nursing, were a psychiatric patient,
possessed a white blood cell (WBC) count ≤ 3.5 × 109/L,
platelet count lower than 90×109/L, hemoglobin count
less than 8.5 g/dL, were taking non-steroidal drugs
long-term, had a known hypersensitivity to the trial
medicine, or if they had participated in other clinical
trials within 4 weeks of screening. The study followed
the ethical guidelines of the Declaration of Helsinki
and the study protocol was approved by the medical
ethics committee of the First Affiliated Hospital of An-
hui University of Chinese Medicine (No.
2012AH-038-01). This study obtained certification
from the Strategic Initiative for Developing Capacity
in Ethical Review (SIDCER) of the World Health Or-
ganization in 2012.
All experiments were completed at the Center of the
First Affiliated Hospital of Anhui University of Tradi-
tional Chinese Medicine, and the Center was approved
in 2012 by the China National Accreditation Commit-
tee (CNAS) of the ISO15189 medical laboratory. The
certificate number is MT0111 CNAS. Clinical Trials.
gov Identifier: NCT01774877.
Measurement of disease severity
Clinical assessments of disease severity and safety mea-
sures were obtained at baseline and at weeks 4, 8, and
12. A standard evaluation of the overall RA severity
was used according to the American Rheumatism Asso-
ciation (ACR) recommended in 2002. It contained the
following criteria: swollen joint count, tender joint
count, Health Assessment Questionnaire (HAQ), C-re-
active protein (CRP) level or erythrocyte sedimenta-
tion rate (ESR), rest pain intensity assessment and over-
all condition of patients as measured on a visual analog
scale (VAS) ranging from 0 mm (no pain) to 100 mm
(severe pain); and the VAS score was integrated by doc-
tors. This was called ACR 20% improvement criteria
(ACR20) when the first two criteria reduced by at least
20% and at least three of the remaining criteria im-
proved by 20%. ACR50 and ACR70 represent a clini-
cal disease activity improvement of at least 50% or
70%, respectively.
The primary efficacy endpoint was the proportion of
patients who had achieved responses according to the
proportion of ACR20 at week 12. The secondary effica-
cy end points were the proportion of patients with
ACR50 and ACR70 at week 12.
Laboratory parameters included: CRP, ESR, rheuma-
toid factor (RF), anti-cyclic citrullinated peptide anti-
body (anti-CCP) antibodies, glucose-6-phosphate
isomerase (GPI), d-dimer, and routine coagulation ex-
aminations.
Life quality assessments included: Health assessment
questionnaire (HAQ), which used to assess the func-
tional status of patients.
The safety assessment included a physical examination
of basic vital signs and electrocardiogram (ECG) before
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the study and at 12-week intervals over the course of
the study. Liver and kidney function tests were taken at
baseline, and subsequently at 4, 8 and 12 weeks.
Treatment
The experimental group took XFC and an LEF place-
bo, orally. XFC was taken as three capsules per dose,
taken 3 times a day immediately after meals for 3
months; 10 mg of the LEF placebo was taken orally,
once a day immediately after a meal, for 3 months.
The control group was orally administered LEF and
XFC placebo. LEF was taken 10mg each time, once a
day immediately after a meal, for 3 months; XFC place-
bo comprised three capsules, taken 3 times per day im-
mediately after meals, for 3 months.
XFC and its placebo were produced by the Preparation
Department of the First Affiliated Hospital of Anhui
University of Chinese Medicine (Anhui Pharmacists;
Certification Z20050062). LEF and its placebo were
produced by Fujian Huitian Biological Pharmacy Co.,
Ltd. (Fujian, China) (drug approval number:
H20050175; 10 mg per pill). The participants were fol-
lowed-up 4 weeks after treatment by telephone.
Trial design
This study was a randomized, controlled, dou-
ble-blind, double-dummy trial. The central randomiza-
tion system was used by the Clinical Evaluation Center
at the China Academy of Chinese Medical Sciences
(CACMS) in Beijing.
Randomization
This research adopted the hierarchical block random-
ized method. The implementation of the random
scheme used the central stochastic system. The statis-
tics personnel at the Clinical Evaluation Center of
CACMS used the statistical software PROC PLAN
program of SAS 9.1.3 (SAS Institute, Inc., Cary, NC,
USA) for randomization. Subjects were randomly di-
vided into four centers and two groups.
Blinding
The patients, researchers and data managers were all
blinded throughout this study.
Statistical analysis
The quantitative data were expressed as mean ± stan-
dard deviation ( xˉ ± s ) Data were analyzed with
SPSS19.0 (SPSS, Chicago, IL, USA) software and
Spearman rank test and t tests were performed. Results
were deemed statistically significant when P < 0.05.
RESULTS
In this study, 45 patients were randomly assigned to
the XFC group (23 cases) or the LEF group (22 cases).
After 12 weeks of treatment, 3 cases from the LEF
group and 2 cases from the XFC group had left the tri-
al. These participants all left because private reasons.
There were no significant differences in demographic
characteristics, vital signs, medical history, or diagnosis
between the two groups. In the two groups at baseline
in the PPS data sets, the patients' overall assessment of
arthritis pain, disease activity, physicians' global assess-
ment of disease activity, time of morning stiffness,
joint pain, joint swelling, joint function classification,
DAS28-3 showed no statistical differences. Thus, we
conclude that the two groups were comparable at base-
line.
Clinical efficacy
The main efficacy index was ACR20 and the second-
ary efficacy indices were ACR50 and ACR70: after 12
weeks of treatment, ACR 20% improvement criteria
(ACR20) was 85% for the XFC treatment group, com-
pared with 85% for the LEF control group. For the
ACR50 criteria, the results were 40% and 70% for the
two groups, respectively, with the ACR70 criteria show-
ing 15% and 25%, respectively. There were no statisti-
cal differences between the two groups (P > 0.05), show-
ing that XFC has equivalent efficacy to LEF (Table 1).
Immunoglobulins (IgA, IgG, IgM)
The results showed that the presence of immunoglobu-
lins, IgA, IgG and IgM in the XFC group and the LEF
group were elevated, especially IgG titers. (In healthy:
IgA 0.7-4.06 g/L, IgG 6.8-14.5 g/L, IgM 0.4-2.5 g/L.)
After 12 weeks of treatment, the two groups showed a
tendency toward reduced immunoglobulin levels, but
no statistical significancewas found (P>0.05) (Table 2).
BAFF/BAFF-R and IgG subtypes
BAFF and BAFF-R were detected by flow cytometry
and the IgG subtypes; IgG1, IgG2, IgG3, IgG4, were
detected by ELISA. The results showed that BAFF and
IgG1, IgG2, IgG3, IgG4 in either of the treatment
groups were not significantly reduced after 12 weeks of
treatment. The levels of BAFF and IgG1 were signifi-
Time point
Week 4
Week 8
Week 12
ACR20
LEF
3 (15)
9 (45)
17 (85)
XFC
5 (25)
12 (60)
17 (85)
ACR50
LEF
1 (5)
2 (10)
8 (40)
XFC
1 (5)
4 (20)
14 (70)
ACR70
LEF
0 (0)
1 (5)
3 (15)
XFC
0 (0)
1 (5)
5 (25)
Notes: ACR: American rheumatism association; LEF: leflunomide; XFC: Xinfeng capsule.
Table 1 ACR20/50/70 distribution at each treatment time point [n (%)]
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cantly reduced in the XFC group compared with the
LEF group, after 12 weeks of treatment (P < 0.05, Ta-
ble 3). This suggests that XFC was able to decrease
IgG1 expression, while LEF had a tendency to increase
it. After 12 weeks, the expression of BAFF-R in the
XFC group was significantly lower than in the LEF
group (P < 0.01, Table 3)
Correlation between immunoglobulin titer and
laboratory index
Correlation analysis showed that IgG2 positively corre-
lated with CRP (P < 0.01); IgG3 positively correlated
with WBC and CRP (P < 0.01); and IgG4 and C4 pos-
itively correlated (P < 0.01). BAFF negatively correlat-
ed with LYMPH# (P < 0.01), while BAFF-R and PLT
and AGP were positively correlated (P < 0.01, Table 4).
DISCUSSION
Despite extensive research into new therapies for the
treatment of autoimmune disease, RA still remains a
Group
LEF
XFC
n
20
20
BAFF
Week 1
169.26±42.28
155.50±38.43
Week 12
194.07±53.38
151.45±43.32a
BAFF-R
Week 1
8.73±4.95
8.77±2.27
Week 12
8.74±2.76
5.12±2.68 bc
IgG1
Week 1
6.58±0.70
7.42±3.98
Week 12
8.53±3.16
6.06±0.79 d
Group
LEF
XFC
n
20
20
IgG2
Week 1
3.05±0.30
2.79±0.26
Week 12
3.10±0.95
3.18±0.81
IgG3
Week 1
2.01±0.28
1.89±0.13
Week 12
2.01±0.67
2.01±0.45
IgG4
Week 1
5.26±0.82
5.03±0.73
Week 12
4.73±0.36
4.88±0.41
Table 3 Comparison of BAFF/BAFF-R and the IgG subtypes（ xˉ ± s）
Notes: LEF group use leflunomide (1 tablets per day) for 1 week till 12 weeks; XFC group use Xinfeng capsule (9 tablets per day) for
1week till 12 weeks.: After 12 weeks treatment, compared with LEF group, BAFF in XFC group is significant lower , aP < 0.05; In Xinfeng
Capsule Group, the expression of BAFF-R after 12 weeks treatment is lower than 1 week treatment, bP < 0.05 , and it also lower than
which in LEF group, cP < 0.01; After 12 weeks treatment, IgG1 in XFC group is lower than it in LEF group, dP < 0.05.
Item
WBC
RBC
HGB
PLT
LYMPH
C3
C4
ASO
RF
AGP
CRP
ESR
IgG1
－0.12
－0.11
－0.21
－0.08
0.03
－0.20
－0.26
－0.05
0.03
0.24
0.20
0.06
IgG2
0.31
－0.03
0.05
0.08
－0.02
0.23
0.26
－0.10
0.12
0.22
0.36a
－0.02
IgG3
0.35a
－0.06
0.01
0.12
－0.03
0.25
0.29
－0.10
0.10
0.21
0.38a
－0.04
IgG4
0.08
－0.02
－0.01
－0.05
0.12
0.15
0.32a
－0.06
－0.04
0.10
0.13
－0.09
BAFF
－0.02
0.07
－0.08
0.04
－0.33a
0.01
0.00
0.17
0.08
0.14
0.04
0.12
BAFF-R
－0.01
－0.10
－0.08
0.28a
－0.09
0.17
－0.03
0.11
－0.03
0.22a
0.14
0.05
Table 4 Correlation between immunoglobulin titer and laboratory index
Notes: WBC: white blood cell; RBC: red blood cell; HGB: hemoglobin; PLT: platelet; YMPH: lymphocyte; C3: complement 3; C4: com-
plement 4; ASO: antistreptolysin O; RF: rheumatoid factor; AGP: 1-acid glycoprotein; CRP: C-reactive protein; ESR: erythrocyte sedi-
mentation rate. a: means there has a correlation between two indexes.
Group
LEF
XFC
n
20
20
IgA
Week 1
3.2±1.5
3.0±1.7
Week 12
2.9±1.8
3.4±1.8
IgG
Week 1
16.5±4.8
14.6±5.5
Week 12
13.8±4.6
15.0±3.6
IgM
Week 1
1.9±1.8
1.6±0.6
Week 12
1.6±1.6
1.8±1.0
Notes: LEF group use leflunomide (1 tablets per day ) for 1week till 12 weekss; XFC group use Xinfeng capsule (9 tablets per day ) for
1week till 12 weeks. LEF: leflunomide; XFC: Xinfeng capsule.
Table 2 Serum immunoglobulins ( xˉ ± s)
629
JTCM |www. journaltcm. com December 15, 2015 |Volume 35 | Issue 6 |
WangYL et al. / Clinical Study
prevalent disease and results in a huge economic bur-
den to the healthcare system in China because of its
long duration, high disability rate and treatment cost.15
Early initiation of disease-modifying anti-rheumatic
drugs prior to the onset of cartilage destruction has
been shown to prevent or significantly diminish the ex-
tent of joint destruction developed during RA.16 The
aim of this study was to explore the utility of treating
RA with XFC and analyzing the level of disease corre-
lates, including IgG subtypes and BAFF/BAFF-R.
IgG1, IgG2, IgG3 and IgG4 are the 4 subtypes of IgG
according to their heavy chain structure. Each subtype
has its own biological characteristics, for example,
IgG1 and IgG3 have the greatest ability to activate
complement and antibody-dependent cellular toxicity.
IgG3 has the shortest half-life, while IgG2 and IgG4
only weakly activate complement and binding to the
surface of macrophages.17 In vivo, IgG is produced by
B lymphocytes. B lymphocyte proliferation and anti-
body production are mediated by BAFF, which has two
forms; a membrane bound form and soluble form. Sol-
uble BAFF (sBAFF; aa83-285) has the same biological
activity as full length BAFF protein. Studies suggest
that sBAFF can enhance the function of B cells, CD4
T cells and NK cells; thus, enhancing the overall im-
mune response.18One study confirmed that the over-ex-
pression of BAFF is closely related to the pathogenesis
of RA.19 BAFF-R is a positive regulator in the differenti-
ation of B cells.
Test results showed that the ACR20, ACR50 and
ACR70 in the XFC group at week 4, week 8, and week
12 were not significantly different from those of the
LEF group (P > 0.05). This suggests that the ACR20,
ACR50, and ACR70 of XFC in other studies are likely
comparable. Furthermore, at each treatment time
point in this study, the ACR20, ACR50 and ACR70 of
the XFC group was not lower than that of the LEF
group.
Based on previous studies,20,21 reference to healthy con-
trol group, we found that IgG levels changed before
and after treatment. The results showed that IgA, IgG
and IgM were increased before XFC treatment, espe-
cially IgG (60% and 45% ). IgG subtypes, including
IgG1, IgG2, IgG3, IgG4, as well as BAFF and
BAFF-R were detected in the blood samples of 40 RA
patients. At 12 weeks after treatment, BAFF and IgG1
from patients in the LEF group and XFC group were
significantly different (P < 0.05). The results showed
that the expression of IgG1 significantly decreased in
the XFC group, while it was slightly elevated in the
LEF group (P > 0.05). The expression of BAFF-R was
significantly decreased in the XFC group after 12
weeks, compared with the LEF group.
XFC is based on a traditional Chinese medicine, Jianpi
Yiqi Tongluo principle,22 which means strengthening
the spleen and replenishing Qi and dredging collater-
als, and is composed of Huangqi (Radix Astragali Mon-
golici), Yiyiren (Semen Coicis), Wugong (Scolopendra)
and Leigongteng (Radix et Rhizoma Tripterygii).
Huangqi (Radix Astragali Mongolici) Yiqi Jianpi, Bu-
zhong Gubiao, which means invigorating Qi and
strengthening spleen, and invigorating Qi for strength-
ening superficies, are thought to downregulate inflam-
matory mediators, such as IL-8, TNF-α, and NO, as
well as increase the expression of glucocorticoid recep-
tors on inflammatory cells.23,24 These inflammatory me-
diators could activate immune response. Yiyiren (Se-
men Coicis) can fortify the spleen and drain dampness,
stimulate the circulation of the blood and cause the
muscles and joints to relax. Leigongteng (Radix et Rhi-
zoma Tripterygii), which can eliminating wind and
dampness, reducing swelling and pain, are thought to
decrease the expression of IL-12, TNF-α. 25,26 It has
been found that the levels of IgM, IgA and IgG in pa-
tients can be improved after treatment through inhibit
immunological response.27,28 In this experiment IgA,
IgG, and IgM were not significantly improved by XFC
treatment; however, a significant decrease in BAFF/
BAFF-R and decreased IgG1 were observed. It is possi-
ble that XFC might lower the level of IgG1 by decreas-
ing BAFF/BAFF-R in RA patients, which may regulate
humoral immunity. Therefore, for rheumatoid arthritis
patients, the Xinfeng capsules can also achieve the an-
ti-inflammatory and analgesic, adjust the immune
function. It provide a new choice for rheumatoid ar-
thritis patients.
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